Pomezia vaccine. Europe buys the doses. Agreement with AstraZeneca signed yesterday in Brussels

Latina Oggi

The EU Commission has signed an agreement for the purchase of 300 million doses of the vaccine produced by the Jenner Institute of Oxford University and the company Advent based in Pomezia (Rome). Under the deal with AstraZeneca, the doses will be distributed to all Member States. Stella Kyriakides, Commissioner for Health and Food Safety, stressed the commitment made by France, Germany, Italy and the Netherlands.

Article published on Latina Oggi28/08/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

The experts warn: “The virus also attacks the brain”

la Repubblica

Repubblica returned to the laboratories of Pomezia, where the first doses of the vaccine candidate have been produced in May. The team has spent a day with Piero Di Lorenzo and Matteo Liguori, respectively CEO and Managing Director of IRBM, and with the 24 biologists working on AZD1222 . Repubblica’s editor, Maurizio Molinari, visited the whole campus, from the clean rooms to the “compound library”. Stefania Di Marco, Scientific Director of Advent-IRBM, is concerned about the latest findings: «The virus not only affects the lungs, but can damage other inner organs, such as the kidneys, liver and, as demonstrated, the brain». «And it is highly transmissible too», reminds Christian Montalbetti, Director of Chemistry. When do we get the vaccine? Now it is an even more pressing question, given these considerations. «A temporary hold of the trials – explains Di Lorenzo – can happen when the sample is large. It’s routine [ …]. If everything goes as planned, Italy will have 3 million doses for those at risk by the end of this year »

Article published on la Repubblica15/09/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Interview with Piero Di Lorenzo, President and CEO of IRBM

The company based in Pomezia (Rome) starts the production

«A great pride and a bet won»

When Piero Di Lorenzo bought IRBM from the multinational Merck eleven years ago, he would never have thought that now he would not even buy the gate of his company with the same money. After synthesizing the Spike protein, Oxford asked Pomezia to develop and characterize the necessary adenovirus. IRBM thus collaborates with both Oxford University and AstraZeneca to develop the vaccine by producing the Spike protein’s viral vector. «So far, we have already passed the strict controls of the British MHRA thrice», says Di Lorenzo. Tests «will end in September, if everything goes as planned. In the meantime, we have already started the production to be prepared».

 

Article published on Il Tirreno – 14/06/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Among the researchers of Pomezia involved in the challenge “Definitive test in Brazil”

la Repubblica

In the IRBM campus, the Advent’s guys cultivate cells like flowers to produce a second stock of experimental vaccine. The first one has already been shipped to Oxford for clinical trials. This second will be sent to Brazil, Kenya and South Africa. The order is to follow the virus where it creates new outbreaks: there the results of vaccine tests will be faster. The researchers have been working tirelessly since the end of January, when Oxford called Stefania Di Marco, Advent’s scientific director, to collaborate. «We are satisfied» says Matteo Liguori, Managing Director of IRBM «We have worked for Oxford so far, now we also work for our country: we have built an emotional bond with Italy thanks to the agreement ». The details of this agreement between AstraZeneca and IRBM for the vaccine production have not yet been disclosed. «We need to invest in our team, with internal and external researchers». IRBM President, Piero Di Lorenzo: «We are proud to be part of such an ambitious challenge»

Article published on la Repubblica14/06/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Italy leads the Coronavirus vaccine research

photo source: Libero Quotidiano

Libero Quotidiano

«The vaccine developed by Oxford in collaboration with an Italian company is the most advanced», said Walter Ricciardi, Advisor to the Minister of Health and member of the WHO’s Executive Board. Advent-IRBM, based in Pomezia (Rome), is the biopharmaceutical company, specializing in vaccines, that works with the British to stop the pandemic. While «we keep testing» says Stefania Di Marco, scientific director of Advent, the multinational AstraZeneca «is involving manufacturing sites worldwide for large-scale production». Piero Di Lorenzo, President of IRBM, is confident that «producing high quality batches for clinical trials will be essential to gain the approval for use in people». «If everything goes as planned, we could have the first doses by next fall-winter», added Ricciardi.

Article published on Libero Quotidiano – 11/06/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Vaccine agreement. It will arrive this autumn Anglo-Italian vaccine, OK of the EU. First doses in autumn

Il Giornale logo

The first doses of the vaccine produced by Oxford in collaboration with Pomezia (Rome) will arrive in Italy by autumn, as announced yesterday by the Italian Minister of Health Roberto Speranza. The Anglo-Italian one is the most advanced of the 136 vaccine candidates currently being tested. And it is working: the 510 volunteers who received the vaccine in April are fine; the results of phase II/III are now expected. The University of Oxford has chosen IRBM as an expert in molecular biotechnology and adenovirus (the viral vector), for vaccine development. A successful partnership that could be beneficial for the whole country, as pointed out by Piero Di Lorenzo, President and CEO of IRBM: «I think that we will play an important role in this project, even in the next distribution».

Article published on il Giornale14/06/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Covid, a young international team: that’s how Pomezia works on the vaccine

[vc_row][vc_column][vc_column_text]In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making history. They have played a key role in the development of the Covid-19 vaccine, after the Jenner Institute (expert in coronavirus) sent them the viral inoculum and asked them for help. IRBM in Pomezia (Rome) has in fact a great experience in adenovirus, the viral vector. «We are producing and shipping the doses: phase III is underway» say Piero Di Lorenzo, President of IRBM, «if everything goes as planned, and it’s a big if, the first doses could be available in Italy between November and December». For IRBM – 43 million turnover reflecting the activity of a centre of excellence – this is an epoch-making challenge.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vcex_button url=”https://www.irbm.com/wp-content/uploads/IL-MATTINO-web_20200723.pdf” download_attribute=”true” icon_right=”fa fa-download” icon_right_padding=”5″]Download the article [/vcex_button][/vc_column][/vc_row]

Comments (0) Rassegna Stampa

Read more

«We are at the forefront in the fight against Ebola, that’s why Oxford asked Pomezia for help with the...

Fonte foto: Il Messaggero

Il Messaggero

Everyone calls it “the Oxford/AstraZeneca vaccine”, but IRBM in Pomezia (Rome)  plays a key role in the vaccine development. This excellence of Italian research, with 250 employees and researchers recruited worldwide, has already achieved relevant results with the Ebola vaccine. «We are a research centre. The Jenner Institute  has been our partner for ten years» says Piero Di Lorenzo, President and CEO of IRBM. «[…] Oxford sent us the viral inoculum, while we had the adenovirus that we had previously tested in the Ebola vaccine […] We have taken part to the anti-covid vaccine development as a research centre. We made a scientific contribution. The Oxford vaccine is not being produced in Pomezia, like I’ve heard. Instead, we have to produce the doses for scientific testing.»

Article published on Il Messaggero – 22/07/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

Here’s the Italian genius who’s gonna get us out of trouble

photo source: Libero Quotidiano

Libero Quotidiano

Italian Minister of Health, Roberto Speranza, announced an agreement with AstraZeneca to provide Europe with up to 400 million doses of the vaccine, together with Germany, France and the Netherlands. The vaccine has been developed by the University of Oxford in collaboration with IRBM in Pomezia (Rome). The entrepreneur Piero Di Lorenzo bought IRBM from the American multinational Merck in 2009: an Italian miracle. In the following years significant results have been achieved: a balanced budget, the hiring of one hundred researchers, collaborations with the Italian Istituto Superiore di Sanità, the National Research Council (CNR) and several universities. With a law degree and countless work experiences as a communication professional, the President of IRBM can be called a lobbyist: he is able to use his skills in order to achieve and make others achieve better results. He also co-wrote the book Lezioni di Lobby with the journalist Mino Fuccillo.

Article published on Libero Quotidiano – 14/06/2020

Download pdf

Comments (0) Rassegna Stampa

Read more

«The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost...

«The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost 2-3 euros, two billion doses will be produced in a year. Italy can rest assured»

photo source: Libero Quotidiano

Libero Quotidiano

«If all goes as planned, large-scale production could start in late September. […] Given the pandemic, I am quite sure the regulatory agencies will reduce the approval time». IRBM, the Italian research institute for medical science and organic chemistry, has contributed to the development of vaccine. During the interview, Di Lorenzo says that the first doses could be available on the market early next year, thanks to AstraZeneca’s huge production capacity. He also talks about the role played by Italy in the vaccine distribution and the good work done by the Italian Minister Speranza.

Article published on Libero Quotidiano – 27/07/2020

Download pdf

Comments (0) Rassegna Stampa

Read more